

BIONIC

NEWSLETTER

A **B**IOlogic drug safety and effectiveness inter**N**ational pharmacoepidemiologic **I**C study in pregnant women with autoimmune disorders or asthma and their children (BIONIC).



Newsflash



BIONIC (Asthma) project funded!



We are thrilled to announce that the **asthma** component of the BIONIC project, led by **Drs. Cristina Longo** and **Sonia Grandi**, has been awarded funding from the Canadian Institutes of Health Research (CIHR).

- This sub-project is titled *Rigorous Evaluation of Asthma biologic Safety and effectiveness Using REal world data on pregnant MOMS and their children (REASSURE-MOMS)*
- Abstract accepted for the International Society for Pharmacoepidemiology (ISPE) 2025 annual meeting

PREVENT project funded!



- Our *PReeclampsia prEVENTion through early education (PREVENT)* project received internal funding from SickKids - Child Health Evaluative Sciences (CHES)

BIONIC OBJECTIVES (EN)

In women with autoimmune disorders or asthma, who continue vs. discontinue biologics in pregnancy, compare the risks of:

- 1) Maternal complications and disease worsening;
- 2) Infant and child complications.

OBJECTIFS DE BIONIC (FR)

Chez les femmes atteintes de maladies auto-immunes ou d'asthme, comparer les risques associés à la poursuite vs. l'arrêt des biologiques pendant la grossesse :

- 1) Complications maternelles et aggravation de la maladie;
- 2) Problèmes de santé chez les nourrissons et les enfants.

We thank our patient-partners (PPs) for their invaluable support and input, which played a crucial role in shaping these projects!

